NCT03174795View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

December 4, 2017

Study Completion Date

December 16, 2017

Conditions
Urinary Tract Infections
Interventions
DRUG

RO7079901

Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.

DRUG

Meropenem

Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.

Trial Locations (14)

1083

Semmelweis University, First Dept of Medicine, Budapest

1115

Szent Imre Egyetemi Oktatokorhaz, Budapest

3414

Liepaja Regional hospital, Liepāja

4012

Kenezy Gyula Korhaz-Rend. Eges. Szol.; Klinikai Farm. Infek. es Allerg. Intezet, Debrecen

11000

Clinical Center of Serbia; Clinic of Urology, Belgrade

11080

Clinical Center Zemun, Belgrade

Clinical Hospital Center Bezanijska Kosa, Belgrade

32216

Jacksonville Center For Clinical Research, Jacksonville

91942

eStudySite, La Mesa

LV-1002

P.Stradina Kliniska Uni Tes Slimnica; Latvian Center of Nephrology, Riga

LV1006

Riga East clinical university hospital, Riga

85-094

Klinika Urologii Ogólnej: Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu; Urology, Bydgoszcz

92-213

Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek, Lodz

02-005

Szpital Kliniczny Dzieciątka Jezus; Oddział Urologii, Warsaw

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03174795 - A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection | Biotech Hunter | Biotech Hunter